Nan Fang Du Shi Bao·2025-12-29 06:27Core Insights - Eli Lilly's weight loss drug Tirzepatide has launched a significant price reduction on the Meituan platform, with prices dropping to around 20% of their initial levels, leading to a more than tenfold increase in order volume [1][4] - The Chinese GLP-1 weight loss market is entering a new phase of competition characterized by "price for volume" strategies, influenced by factors such as Tirzepatide's inclusion in the national medical insurance directory and the impending patent expiration of Semaglutide [5][7] Pricing and Sales Dynamics - Tirzepatide's prices on Meituan for various specifications are set at 450 yuan, 750 yuan, 1050 yuan, and 1320 yuan, which are approximately 20% of the prices at the beginning of the year [2] - Other e-commerce platforms have slightly higher prices for the same specifications, indicating a competitive pricing landscape [4] - The price drop has stimulated consumer demand significantly, with order volumes on Meituan increasing over tenfold following the price reduction [4] Market Competition and Trends - The GLP-1 market is experiencing intense competition, with Tirzepatide contributing significantly to Eli Lilly's revenue, accounting for half of its total sales in the first three quarters of the year [5] - Novo Nordisk's Semaglutide has also seen price reductions, with its 1.5ml injection priced around 220 yuan, down approximately 70% from the mid-year price [4] - The market is expected to see a surge in competition as Semaglutide's core patent expires in March 2024, leading to an influx of generic drugs [7] Consumer Behavior and Online Market - The online channel has become a crucial battleground for GLP-1 drugs, with over 80% of users actively seeking information about weight management products online [7][8] - Female users dominate the online purchasing demographic, with women making up about three times the number of male users in the weight loss sector [8] - Platforms like Meituan are enhancing user experience by integrating services such as patient education and cold chain logistics for drug delivery, addressing the specific needs of GLP-1 medication [8] Future Outlook - The GLP-1 market is projected to exceed 30 billion yuan by 2030, with online medical channels expected to capture over 50% of this market share [7] - The Chinese government's initiatives, such as the "Weight Management Year" starting in 2024, aim to address the rising obesity rates, further driving the demand for GLP-1 drugs [8]